SNIPR Biome receives up to EUR 20 million from European Investment Bank (EIB) to advance therapies against microbial resistance / 12.24

SNIPR Biome will use the EIB funds to develop new medicines for infections where existing antibiotics are no longer effective. The EIB’s financing is backed under HERA Invest, part of the European Commission’s InvestEU initiative.

SNIPR Biome receives funding for the development of CRISPR-medicines to improve Environmental Enteric Dysfunction (EED) in pregnant women / 06.24

SNIPR BIOME receives funding from the Bill & Melinda Gates Foundation to accelerate the development of SNIPR Biome's microbial gene therapy platform to improve EED in pregnant women from low- and middle-income countries (LMICs).

SNIPR Biome receives USD 5.48 million funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials / 04.24

The 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation

SNIPR Biome extends collaboration with Novo Nordisk to continue advancing microbial gene therapy approach / 08.23

The funded research agreement further validates SNIPR’s microbial gene therapy technologies and builds upon the research collaboration that the two companies began in June 2021.

Precedential US Federal Court Decision Hands SNIPR Biome a win in patent appeal over Rockefeller University for CRISPR-Cas microbial gene editing / 07.23

Five contested patents held by SNIPR remain in place

Precedential ruling means that SNIPR’s patent portfolio will not be subject to any further interference and will not be judged by the old first-to-invent standard

SNIPR Biome reports positive clinical interim results for groundbreaking, first-in-human, CRISPR-based microbial gene therapy / 05.23

SNIPR001 demonstrates proof of principle in reducing E. coli levels in the human gastrointestinal tract

SNIPR Biome has research findings published in Nature Biotechnology / 05.23

SNIPR Biome's data on first clinical drug candidate to prevent infections in hematological cancer patients published in Nature Biotechnology

SNIPR Biome featured in Sciencereport.dk / 04.23

Article examines four key elements of the Danish ecosystem which have contributed to SNIPR Biome's accomplishments

SNIPR Biome presents at BioCapital Europe 2023 / 03.23

CEO Christian Groendahl presents current status of company (between 2:17:30 and 2:41:15 in video)

SNIPR Biome participates at LIF Sweden event “AMR: new incentives – a call for action” / 02.23

Speakers from SNIPR Biome, Pfizer, CARB-X and EFPIA discuss incentives to drive innovation in the AMR space

SNIPR Biome further strengthens CRISPR/Cas IP portfolio with patent grant / 12.22

Patent issuance adds to SNIPR’s extensive intellectual property portfolio, comprising more than 60 granted worldwide patents, including in the USA and Europe. Patent covers the use of killing of bacteria at least 1000-fold in a microbiome using any CRISPR/Cas system. USPTO has also issued a Notice of Allowance for methods of using CRISPR lytic phage

Chardan's 6th Annual Genetic Medicines Conference - SNIPR Biome / 12.22

SNIPR Biome participated in the Genetic Medicines Conference and talked about the company, progress of the pipeline and more.

Synthego podcast with our CEO Christian Groendahl On Pioneering a CRISPR-based Microbial Gene Therapy / 12.22

Listen in below to hear more about Christian Groendahl and his work in biotech and pionering the CRISPR field. You can also find the podcast in most common podcast apps.

SNIPR Biome Launches A Non-Profit Patent Licensing Program To Enable The Field of CRISPR Editing in Prokaryotes / 10.22

Company announces that its patent portfolio covering the use of CRISPR/Cas systems to edit prokaryotes is now available for academic and non-profit research use without a written license.

SNIPR Biome featured on Genetic Engineering & Biotechnology News / 09.22

We were featured on Genetic Engineering & Biotechnology News’ 10 year review of the many exciting developments and use of CRISPR technology

SNIPR Biome featured on Drug Target Review podcast / 08.22

Our CRISPR and Delivery expert and Head of CRISPR and Delivery Technologies, Jakob Haaber, was featured on the Drug Target Review podcast, covering CRISPR in therapeutic settings and in pharmaceutical discovery

SNIPR Biome Granted New US Patent Covering Lytic CRISPR Phage / 08.22

SNIPR Biome further strengthening its intellectual property portfolio which now contains more than 20 granted patents in the USA and Europe for editing prokaryotes using CRISPR/Cas

SNIPR Biome interviews in Danish newspaper Børsen / 06.22

On the company’s plans for fundraising in the current volatile environment and patent interference update

BioCentury article on prokaryotic CRISPR patent interference / 05.22

Article highlights current patent interference between SNIPR and Rockefeller University

SNIPR Biome presents at the 22nd BioEquity Europe / 05.22

Founder and CEO, Christian Grøndahl, presents current status of pipeline and company

SNIPR Biome Initiates First-in-Human Clinical Trial with SNIPR001 / 04.22

SNIPR Biome, a leading CRISPR and microbiome gene therapy biotechnology company, today announced dosing of the first human subjects in its phase 1 clinical trial with SNIPR001, an orally administered CRISPR-based therapeutic.

SNIPR Biome expands its Executive Management team and opens offices in the US and UK / 03.22

Appointment of Jasper Clube as Chief Intellectual Property Officer from 1 February 2022 and Stephanie Krebs as Chief Business Officer from 14 March 2022. In addition, SNIPR Biome will open offices in the US and the UK effective immediately.

SNIPR Biome presents at Chardan’s Metagenomics and Microbiome Medicines Summit / 03.22

Co-founder and CEO, Christian Grøndahl, presented the SNIPR Biome pipeline and key achievements.

SNIPR Biome announces opening of new BSL2/GMO2-classified laboratory in Copenhagen, Denmark / 03.22

SNIPR Biome, a leading CRISPR and microbiome biotechnology company, is opening a 175 square meter state-of-the-art BSL2/GMO2-classified laboratory in Copenhagen.

SNIPR Biome Announces U.S Food and Drug Administration grants Fast Track Designation for SNIPR001 / 01.22

SNIPR001 is the company’s first development candidate targeting E. coli in patients with hematological malignancy at risk of neutropenia.

SNIPR Biome Announces FDA Clearance of Investigational New Drug (IND) application / 01.22

Clearance is for SNIPR001, a Novel CRISPR Therapy Targeting Life-Threatening E. coli Infections

SNIPR Biome granted broad fundamental patent rights from European Patent Office / 12.21

SNIPR Biome Announces Pioneering Work on CRISPR Targeting of Microbiomes is Recognised as European Patent Office Grants Fundamental Patent Rights

SNIPR Biome presentation @ BARDA Industry Day 2021 / 11.21

See how SNIPR Biome is working on re-inventing antimicrobial agents using CRISPR Technology. Milan Zdravkovic (CMO), presented our work at the recent BARDA Industry Day 2021.

MD Anderson and SNIPR Biome collaborate to advance next-generation CRISPR microbiome therapeutics / 09.21

Research focused on improving immunotherapy-related side effects for patients with cancer

SNIPR Biome enters into research agreement with Novo Nordisk / 06.21

SNIPR Biome and Novo Nordisk have entered into a research agreement on an undisclosed target to evaluate SNIPR BIOME’s proprietary technology for in situ production of therapeutics in the human microbiome

SNIPR Biome receives grant from CARB-X / 05.21

SNIPR Biome has been awarded up to 10.2 mUSD from CARB-X for a novel precision and microbiome sparing therapy against E. coli in people with hematological cancer

BioCapital 2021 presentation / 03.21

Christian Grøndahl, CEO, presentation at BioCapital conference

Press Release / 10.20

SNIPR Biome appoints Dr. Milan Zdravkovic as Chief Medical Officer

Press Release / 09.20

Dr. Per Falk elected to SNIPR Biome board of directors

Future Talks / 06.20

IDA Future Talks with Christian Grøndahl

Press Release / 01.20

SNIPR Biome Strengthens Lead in CRISPR-based Medicines to Treat Microbiomes

Nome Magazine / 12.19

Back to the basics: CRISPR in bacteria can become the next big pharmaceutical breakthrough

Business Insights / 12.19

CRISPR Technology: Assassinating Superbugs and Creating a New Paradigm

EY / 11.19

EY Entrepreneur Of The Year 2019 / Life Sciences – video presentation of
SNIPR Biome [in Danish]

EY / 11.19

EY Entrepreneur Of The Year 2019 / Life Sciences – video of award show [in Danish / English]

EY / 11.19

SNIPR BIOME wins the prestigious "EY Entrepreneur Of The Year 2019 / Life Sciences" award

CRISPR Medicine Blog / 11.19

Turning CRISPR into a bacteria killer. A new principle in antibiotics

Finans / 11.19

Danish biotech company to develop ground-breaking replacement for penicillin
[in Danish]

IDA / 08.19

Danish CRISPR startup to develop replacement for penicillin [in Danish]

Pharma / 06.19

The biotech company SNIPR Biome wants to hit bacteria precisely [in Danish]

Press Release / 05.19

US Patent Grants Strengthen SNIPR BIOME’s Approach to Enhance Immuno-Oncology Outcomes by Microbiome Modulation

BioCentury Innovations / 05.19

SNIPR: Turning CRISPR into a microbiome suicide

FierceBiotech / 03.19

SNIPR raises $50M to use CRISPR to modulate the microbiome

BioCentury / 03.19

$50M series A for CRISPR microbiome play SNIPR BIOME

Endpoint News / 03.19

Lundbeck fund backs a $50M launch round for SNIPR Biome, a new brand of CRISPR Cas biotech

Press Release / 03.19

SNIPR BIOME raises $50 million Series A financing to advance CRISPR-based microbiome drugs to human clinical trials